Metabolic syndrome (MetS) has the largest global burden of all noncommunicable diseases. Owing to the clinical heterogeneity of MetS, wide variations have been reported in the efficacy of moderate-to-vigorous physical activity (MVPA) and intermittent fasting (IF) for improving MetS. We searched five databases for randomized controlled trials published through December 2021, and 372 participants from 11 studies were included in this meta-analysis. Compared with MVPA alone, IF combined with MVPA had a more significant effect on improving body mass and levels of fasting blood glucose and high-density lipoprotein cholesterol; however, it was ineffective in improving triglycerides level, systolic blood pressure, and diastolic blood pressure. Subgroup analysis showed that, except for blood pressure, time-restricted fasting combined with MVPA had a better effect than alternate-day fasting with MVPA. Meanwhile, when the intervention lasted longer than 8 weeks, the effect of the combined intervention was significantly better than that of MVPA alone. This finding provides a basis for clinicians to manage the health of overweight individuals. This study also showed that Caucasians may be more suitable for the combined intervention than Asians. And the combined intervention may provide a preventive effect for MetS risk factors in healthy populations, although this may be due to the small sample size. In general, this study provides a novel perspective on special interventions for MetS traits.
Background N1-methyladenosine (m1A) RNA methylation is crucial in the carcinogenesis and tumorous molecular pathogenesis. However, the detailed pathogenic mechanism of m1A regulators in pancreatic adenocarcinoma (PAAD) has not been comprehensively researched. Therefore, the purpose of this study was to investigate the role of m1A in PAAD prognosis and tumor microenvironment (TME).Methods The relationship between m1A regulators and the PAAD prognosis was analyzed with cBioportal database. RNA-seq transcriptome was obtained from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases for differential expression analysis. The role of m1A regulators in the PAAD TME was analyzed with TISIDB database and R software. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were performed by The Database for Annotation, Visualization, and Integrated Discovery (DAVID).Results In PAAD, we discovered 10 m1A regulators correlated to poor prognosis and were all upregulated. While up-regulated ALKBH1 and TRMT10B were associated with a better prognosis in PAAD patients. Further research found that ALKBH1 and TRMT10B significantly upregulated the infiltrating level of immune cells, especially CD4+ T cells. Additionally, they also affected the expression of immunomodulators, including CD276, TMEM173, TNFSF9, etc. Finally, GO and KEGG enrichment analysis proved that ALKBH1 and TRMT10B influenced the PAAD development by regulating the RNA polymerase II.Conclusion Promoted expression of ALKBH1 and TRMT10B was significantly related with a better prognosis in PAAD, the possible mechanism of which might associate with the alternation of the TME. ALKBH1 and TRMT10B were potential prognosis biomarkers and possible immunotherapeutic targets for PAAD.
Background N1-methyladenosine (m1A) RNA methylation is crucial in the carcinogenesis and tumorous molecular pathogenesis. However, the detailed pathogenic mechanism of m1A regulators in pancreatic adenocarcinoma (PAAD) has not been comprehensively researched. Therefore, the purpose of this study was to investigate the role of m1A in PAAD prognosis and tumor microenvironment (TME).Methods The relationship between m1A regulators and the PAAD prognosis was analyzed with cBioportal database. RNA-seq transcriptome was obtained from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases for differential expression analysis. The role of m1A regulators in the PAAD TME was analyzed with TISIDB database and R software. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were performed by The Database for Annotation, Visualization, and Integrated Discovery (DAVID).Results In PAAD, we discovered 10 m1A regulators correlated to poor prognosis and were all upregulated. While up-regulated ALKBH1 and TRMT10B were associated with a better prognosis in PAAD patients. Further research found that ALKBH1 and TRMT10B significantly upregulated the infiltrating level of immune cells, especially CD4+ T cells. Additionally, they also affected the expression of immunomodulators, including CD276, TMEM173, TNFSF9, etc. Finally, GO and KEGG enrichment analysis proved that ALKBH1 and TRMT10B influenced the PAAD development by regulating the RNA polymerase II.Conclusion Promoted expression of ALKBH1 and TRMT10B was significantly related with a better prognosis in PAAD, the possible mechanism of which might associate with the alternation of the TME. ALKBH1 and TRMT10B were potential prognosis biomarkers and possible immunotherapeutic targets for PAAD.
Background N1-methyladenosine (m1A) RNA methylation is crucial in carcinogenesis and tumorous molecular pathogenesis. However, the detailed pathogenic mechanism of m1A regulators in pancreatic adenocarcinoma (PAAD) has not been comprehensively researched. Therefore, the purpose of this study was to investigate the role of m1A in PAAD prognosis and tumor microenvironment (TME). Methods The relationship between m1A regulators and the PAAD prognosis was analyzed with the cBioportal database. RNA-seq transcriptome was obtained from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases for differential expression analysis. The role of m1A regulators in the PAAD TME was analyzed wthe ith TISIDB database and R software. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichmanalysesysis were performed by The Database for Annotation, Visualization, and Integrated Discovery (DAVID). Results In PAAD, we discovered 10 m1A regulators correlated to poor prognosis and were all upregulated. While up-regulated ALKBH1 and TRMT10B were associated with a better prognosis in PAAD patients. Further research found that ALKBH1 and TRMT10B significantly upregulated the infiltrating level of immune cells, especially CD4 + T cells. Additionally, they also affected the expression of immunomodulators, including CD276, TMEM173, TNFSF9, etc. Finally, GO and KEGG enrichment analysis proved that ALKBH1 and TRMT10B influenced the PAAD development by regulating the RNA polymerase II. Conclusion Promoted expression of ALKBH1 and TRMT10B was significantly related to a better prognosis in PAAD, the possible mechanism of which might associate with the alternation of the TME. ALKBH1 and TRMT10B were potential prognosis biomarkers and possible immunotherapeutic targets for PAAD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.